University Chicago Hospital Dept of Oncology
Welcome,         Profile    Billing    Logout  
 9 Trials 
10 Trials

   

 
Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
Jakubowiak, Andrzej J
ATLAS, NCT02659293: Trial of Carfilzomib, Lenalidomide, Dexamethasone Versus Lenalidomide Alone After Stem-cell Transplant for Multiple Myeloma

Active, not recruiting
3
180
Europe, US
Lenalidomide, Revlimid, Carfilzomib, Kyprolis, Dexamethasone, Lenalidomide (Control)
University of Chicago
Multiple Myeloma
11/24
11/26
(COBRA), NCT03729804: Carfilzomib, Lenalidomide, and Dexamethasone Versus Bortezomib, Lenalidomide and Dexamethasone (KRd vs. VRd) in Patients With Newly Diagnosed Multiple Myeloma

Active, not recruiting
3
250
US
Carfilzomib, Kyprolis, Lenalidomide, CC-5013, Revlimid, Dexamethasone, Bortezomib, Velcade, PS-341
University of Chicago
Multiple Myeloma
07/25
07/26
NCT01816971: Carfilzomib, Lenalidomide, and Dexamethasone Before and After Stem Cell Transplant in Treating Patients With Newly Diagnosed Multiple Myeloma

Checkmark EHA 2014
May 2014 - May 2014: EHA 2014
Active, not recruiting
2
76
Canada, US
dexamethasone, Aeroseb-Dex, Decaderm, Decadron, DM, DXM, carfilzomib, Kyprolis, PR-171, lenalidomide, CC-5013, IMiD-1, Revlimid, autologous hematopoietic stem cell transplantation, laboratory biomarker analysis
University of Chicago, National Cancer Institute (NCI)
Stage I Multiple Myeloma, Stage II Multiple Myeloma, Stage III Multiple Myeloma
04/18
12/26
NCT02389517: Lenalidomide With or Without Ixazomib Citrate and Dexamethasone in Treating Patients With Residual Multiple Myeloma After Donor Stem Cell Transplant

Active, not recruiting
2
42
US
Ixazomib Citrate, MLN-9708, MLN9708, proteasome inhibitor MLN9708, Lenalidomide, CC-5013, CC5013, CDC 501, IMiD-1, Dexamethasone, DM
University of Chicago, National Cancer Institute (NCI), Multiple Myeloma Research Foundation
Plasma Cell Myeloma, Residual Disease
03/25
03/25
Elo-KRd, NCT02969837: Study of Initial Treatment With Elotuzumab, Carfilzomib, Lenalidomide and Dexamethasone in Multiple Myeloma

Active, not recruiting
2
47
US
Elotuzumab, Empliciti, Carfilzomib, Kryprolis, Lenalidomide, Revlimid, Dexamethasone
University of Chicago, Bristol-Myers Squibb, Amgen, Multiple Myeloma Research Foundation
Multiple Myeloma
03/25
03/29
NCT03500445: Daratumumab, Carfilzomib, Lenalidomide and Low Dose Dexamethasone (DKRd) in Newly Diagnosed, Multiple Myeloma

Active, not recruiting
2
75
US
Daratumumab, DARZALEX®, Carfilzomib, KYPROLIS®, Lenalidomide, REVLIMID®, Dexamethasone
University of Chicago, Janssen Scientific Affairs, LLC, Amgen
Myeloma, Multiple Myeloma
06/25
06/25
NCT01665794: Carfilzomib, Pomalidomide, and Dexamethasone in Treating Patients With Relapsed or Refractory Multiple Myeloma

Checkmark ASCO 2016
May 2016 - May 2016: ASCO 2016
Active, not recruiting
1/2
101
Canada, US
Pomalidomide, CC-4047, Pomalyst(R), Carfilzomib, Kyprolis (R), PR-171, dexamethasone, Aeroseb-Dex, Decaderm, Decadron, DM, DXM, Daratumumab, Daralex
University of Chicago, National Cancer Institute (NCI), Multiple Myeloma Research Foundation
Multiple Myeloma
11/24
11/24
NCT05027594: Ph I Study in Adult Patients With Relapsed or Refractory Multiple Myeloma

Terminated
1
5
US
NMS-03597812, NMS-03597812 + dexamethasone
Nerviano Medical Sciences
Multiple Myeloma
08/23
01/24
SINE, NCT02199665: Selinexor, Carfilzomib, and Dexamethasone in Treating Patients With Relapsed or Refractory Multiple Myeloma

Checkmark Selinexor in combination with carfilzomib and dexamethasone for relapsed/refractory MM
Dec 2015 - Dec 2015: Selinexor in combination with carfilzomib and dexamethasone for relapsed/refractory MM
Recruiting
1
100
US
selinexor, CRM1 nuclear export inhibitor KPT-330, KPT-330, selective inhibitor of nuclear export KPT-330, SINE KPT-330, carfilzomib, Kyprolis, PR-171, dexamethasone, Aeroseb-Dex, Decaderm, Decadron, DM, DXM
University of Chicago, National Cancer Institute (NCI)
Refractory Multiple Myeloma
07/25
12/25
MRD2STOP, NCT04108624: Study to Assess for Measurable Residual Disease (MRD) in Multiple Myeloma Patients

Active, not recruiting
N/A
56
US
Screening Phase, Discontinuation Phase
University of Chicago
Multiple Myeloma
07/25
07/25

Download Options